BioSpace News Archive

Cytonus Therapeutics Inc. (Cytonus), a biotechnology company developing therapeutic products for targeted delivery in vivo, announces that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR meeting in New Orleans.

Guerbet has recently submitted a New Drug Application to the U.S. Food and Drug Administration and a Centralized Application for Marketing Authorization to the European Medicine Agency for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent.

The global home healthcare market gathered revenue around USD 181.0 Billion in 2020 and market is set to grow USD 275.2 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 8.0% during the prediction period 2021 to 2027.

Proteins are the most important and largest biomolecules and extremely vital to the functioning of an organism.

Researchers have been identifying the different areas in airways and lungs to develop drugs for offering a better quality of life to patients suffering from asthma and chronic obstructive pulmonary disease (COPD).

Motus GI Holdings, Inc. reported its financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

Tricida, Inc. announced financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives.

Pardes Biosciences, Inc. (NASDAQ: PRDS), today reported financial results for the full year ended December 31, 2021 and provided a business update.

argenx SE announced that the underwriters of its previously announced global offering of ordinary shares have exercised in full their option to purchase 350,000 additional ordinary shares in the form of ADSs on the same terms and conditions as the global offering.

RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing.